ÂÜÀòÂÒÂ×

Jerry Parrott is President, Chief Executive Officer and a Director of BioMarker Strategies. Mr. Parrott previously served Human Genome Sciences, Inc. as Vice President, Corporate Affairs and Public Policy from 2001 until the acquisition of HGSI by GlaxoSmithKline in 2012. He formerly held senior public policy, corporate affairs, and other positions with Bristol-Myers Squibb Company, American Hospital Supply Corporation and Walgreen Company. As Principal of his own consultancy from 1995-2001, Mr. Parrott’s clients included HGSI, Bristol-Myers Squibb, Ciba-Geigy, Diversa, Genentech, HealthCare Ventures, Hoffmann-La Roche, Rock Hill Ventures, Western Digital, Wyeth and others. During this period, he helped take public 3-Dimensional Pharmaceuticals, subsequently acquired by Johnson & Johnson, and InforMax, subsequently acquired by Invitrogen. He has helped launch important therapeutic products in immunology, oncology, infectious disease and pain relief, and has helped bring two prescription products over the counter.

Since 2006, Mr. Parrott has served as Chairman and President of Maryland Health Care Product Development Corporation, a nonprofit venture capital fund committed to helping health care products companies grow and succeed in Maryland. He is a Director of MdBio and the Maryland Technology Council. He formerly served as Senior Advisor to the Maryland Life Sciences Advisory Board, Chair of the Biotechnology Industry Organization (BIO) Committee on Outreach and Alliance Development, Chair of the Rx Partners health care reform coalition, Founding Director of BioHealth Innovation, Founding Trustee of the Foundation for Genetic Medicine, and Trustee of the Committee for Economic Development.